Intelligence · Clinical pipeline

Every cannabinoid trial, product and sponsor, tracked live, so you see the pipeline move before the press release does.

Every cannabinoid clinical trial, every investigational product and every company developing one, pulled from 13 trial registries and regulator records, tagged record by record, and kept current.

13trial registries
merged
48countries
covered
114investigational
products
83companies
developing them

Already have access? Open the tracker →

Decide · Clinical trials
2,250+cannabinoid trials on record
427recruiting now
719completed

Trial starts by year

20142025: 176 starts, the record2026

Largest live Phase III trials, by enrolment

VER-01 radicularRadicular low-back pain810Registered
PROMOTEClinical high-risk psychosis586Registered
ZYN002 open-label ext.Fragile X syndrome550Recruiting
CBD TPM capsulesPrimary insomnia519Recruiting

13 registries merged into one record per trial. Website snapshot of 24 Aug 2026.

The problem

There is no register of cannabinoid trials, so we built one.

Ask how many cannabinoid trials are running and you will get a different answer from every source, because every source counts a different thing. ClinicalTrials.gov holds 1,546 of the records here and misses 750 more that only exist in the Australian, German, Indian, Dutch, Brazilian, Iranian or EU registers.

1
One record per trial, 13 registries deepMerged from 13 sources, so a European pivotal study does not disappear because it never reached a US register.
2
Tagged, not just indexedPhase, status, condition group, cannabinoid, compound class, dosage form, delivery route, design, blinding, funder type, sponsor and country, on every record.
3
Linked to products and companiesEach trial connects to the investigational product it tests and the company behind it, so a pipeline question and a competitor question are the same query.

Where the 2,296 records come from

1,546750
ClinicalTrials.gov750 trials a ClinicalTrials.gov search never returns
ANZCTR197
EU CTR (EudraCT)99
NTR (Netherlands)82
ISRCTN69
DRKS (Germany)68
CTRI (India)58
Other51
IRCT (Iran)43
REBEC (Brazil)36
CTIS (EU)27
UMIN (Japan)12
ChiCTR (China)8

What the data shows

Record activity, and a pipeline that is still thin where it counts.

The analysis below is drawn straight from the tracked base. Every chart carries the figure it was built from and the basis it was counted on.

Trial starts by year, split by phase

05010015020037201451201554201659201792201810620191152020169202116620221682023152202417620251182026

Swipe the chart sideways →

Phase IPhase IIPhase IIIPhase IVObservational and other

Cannabinoid research did not peak and fade. Starts climbed from 54 in 2016 to a record 176 in 2025 and have held above 150 a year since 2021. But look at the gold band: Phase III has never exceeded 26 starts in a year. The field is getting bigger, not further along.

Basis: registered start year. 537 of 2,296 records carry no start date and are excluded; 2026 counts every start registered for the year, including dates still ahead. Cannamonitor Clinical Trials database, 13 registry sources, n = 2,296. Snapshot 24 Aug 2026.

Three things the record says

176Starts hit a record in 2025176 trials began that year against 54 a decade earlier, and 118 are already registered for 2026.
16%Only 16% of it is late-phase364 of 2,296 trials are Phase III or IV. The pipeline grew at the exploratory end, not the registration end.
36%Because the money is academicIndustry funds 19% of trials overall but 36% of the late-phase work. Nobody else pays for a pivotal trial.

Where the pipeline sits

16%Phase III or IV

Phase II 625Other 613Phase I 382Observational 310Phase III 276Phase IV 88

Phase II is the structural engine at 625 trials. Pivotal work, Phase III and IV together, is 364, or 16% of everything on record.

Two preclinical records are too few to draw. ‘Other’ covers trials carrying no conventional phase label.

What it is being tested on

Substance use616
Pain447
Neurology370
Mental health352
Other342
Healthy / mechanistic274
Oncology184
Sleep99
Rare disease92

The largest single block is not a therapy. Substance-use research (616) plus healthy-volunteer and mechanistic work (274) accounts for 39% of all tags: research about cannabis, not medicine made from it.

Condition groups are multi-tag, so tags exceed the trial count. Nine of 15 groups shown.

Who pays for it

Academic / university1,537183
Industry433130
Government / public40459
Unknown14211
Non-profit / foundation475

All trialsPhase III / IV

Academia runs the pipeline and industry runs the end of it. Universities fund 1,537 trials but only 183 late-phase ones. Industry funds 433, and 36% of all late-phase work.

Funder type is multi-tag. A trial with no recorded funder is excluded from both bars.

The two biggest sponsors, side by side

Yale University710
Jazz Pharmaceuticals6543
Johns Hopkins University452
New York State Psychiatric Inst.424
Medical Univ. of South Carolina386
University of Colorado, Denver334

Trials sponsoredof them Phase III / IV

Yale has sponsored 71 cannabinoid trials and not one of them is late-phase. Jazz has sponsored 65 and 43 of them are. That contrast is the structural problem in one row.

Sponsor as recorded on the registry entry.

What is being put in the capsule

54%19%20%
Before 2016
48%26%15%
2016–2020
48%35%6%
2021–2026

Whole-plantIsolateSynthetic

Synthetic cannabinoids have fallen from 20% of starts to 6% while isolates nearly doubled to 35%. Whole-plant preparations held roughly half the field throughout.

Share of trials with a registered start date in each era, by compound class (99.9% field coverage). The THC:CBD ratio field covers only 48% of the base and is not used.

The molecules actually under study

CBD1,217
THC815
Dronabinol (syn.)129
Nabiximols95
ECS modulator79
CBN52
Nabilone (syn.)43
CBG15
THCV7

CBD is the most-studied cannabinoid (1,217 trials), ahead of THC (815). Behind them the minor-cannabinoid tail is real but still small: 90 trials across CBN, CBG, THCV, CBDV, delta-8-THC, CBDA and CBC combined.

Multi-tag: a trial testing a THC:CBD product carries both. 588 trials record no specific cannabinoid.

How rigorous it actually is

42%48%
Phase I
68%74%
Phase II
74%85%
Phase III
38%50%
Phase IV

Placebo-controlledRandomised

The charge that cannabinoid evidence is anecdotal does not survive the phase data. 74% of Phase III trials are placebo-controlled, against 68% at Phase II and 42% at Phase I. The closer to approval, the tighter the control.

Share of each phase’s trials.

How big the trials actually are

44
Phase I
82
Phase II
174
Phase III
69
Phase IV

The average cannabinoid Phase III enrols 174 patients. A mainstream pivotal trial runs several times that. Across all 1,371 Phase I to IV trials on record, total enrolment is 111,886 people.

Mean recorded sample size per phase, from the 1,252 phased trials that record one. Observational studies are excluded.

Volume and maturity live in different places

United States8%74/908
Canada11%18/161
Germany17%23/136
United Kingdom43%49/113
Netherlands12%11/95
Israel15%11/73
Australia23%15/66
India34%22/65
France8%5/60
Brazil18%10/55

The country that runs the most trials runs the least pivotal work. 8% of US trials are Phase III, against 43% in the UK and 17% in Germany. Europe carries 185 Phase III site-tags to North America’s 92.

Phase III as a share of each country’s trial tags; the bar axis stops at 50%. 1,957 of 2,296 records carry a country.

What comes back out

30%of completed trials have posted results

30%46%24%

Results posted 216No results posted 333Not recorded 170

719completed trials on record
216have posted results
269records carry a publication or DOI

Of 719 completed trials, only 216 have posted results, which is 30%. Seven in ten finished studies have never returned a public read, and only 269 records across the whole base carry a publication or DOI.

Completed trials only. ‘Not recorded’ means the registry entry carries no results field.

Every chart above is an extract from the tracker.The tracker holds the products, the companies and the full trial analysis behind them.
Get the pipeline tracker →

The products

Eighty-seven products in development, and twelve at the final hurdle.

A trial is an event and a product is a bet. The investigational-products tracker holds every cannabinoid asset in human development: what it is made of, how it is delivered, what it is aimed at, and how far it has got.

114products
tracked
87in clinical
trials
7approved
anywhere
7discontinued
Preclinical2in the tracker before first-in-human
Phase I24have got as far as first-in-human
Phase II58of 114 products have got no further
Phase III17reached it: 12 live, 5 discontinued
Approved7hold an authorisation in any market

What they are made of

CBD isolate387
Full-spectrum / botanical326
Synthetic small molecule202
THC isolate (dronabinol)106
THC:CBD combination83
Biologic10

All productsApproved or Phase III

What they are aimed at

Pain25
Neurology24
Oncology10
Mental health6
Inflammatory6
GI & metabolic5
Sleep4
Dermatology4

CBD isolates lead on count, at 38 products. But look at the gold bars: the plant-derived classes convert to a late-stage asset at close to one in five, while only 2 of the 20 synthetic small molecules have got there, and one of those two is discontinued.

Composition class and lead condition group as recorded on the product. 5 products carry no class; 6 carry no recorded stage. Eight of 11 condition groups shown.

Investigational products · live at Phase III
ProgrammeSponsorLead indicationClass
Exilby follow-onVertanical · GermanyRadicular low-back painFull-spectrum
CANPAINCeladon · UKChronic non-cancer painFull-spectrum
NTI164Neurotech International · AustraliaPaediatric neurodevelopmentFull-spectrum
YCJ-01Oils4Cure · SpainTSC epilepsy (adjunct)Full-spectrum
CannadorBionorica · GermanyMS spasticityFull-spectrum
IHL-42XIncannex Healthcare · AustraliaObstructive sleep apnoeaTHC isolate
AP707 / CannaXanApurano Pharmaceuticals · GermanyChronic / neuropathic painTHC isolate
BX-1Bionorica · GermanyMS spasticityTHC isolate
NanaBisMGC Pharmaceuticals · AustraliaCancer bone painTHC:CBD
JZP378Jazz Pharmaceuticals · US / UKMS spasticity (US)THC:CBD
CardiolRxCardiol Therapeutics · CanadaRecurrent pericarditisCBD isolate
TPM cannabidiol capsuleAvecho Biotechnology · AustraliaInsomniaCBD isolate
  • Zygel (ZYN002) Fragile X syndrome
  • Lenabasum (JBT-101) Systemic sclerosis
  • QIXLEEF (PPP001) Advanced cancer pain
  • MRX2 Paediatric epilepsy
  • Cannabidiol Oral Solution Paediatric epilepsy

5 Phase III programmes are recorded as discontinued. A pipeline view that quietly drops its failures tells a rosier story than the field has had.

The shelf

Seven approved products in forty years, and four of them are synthetic THC or its analogue.

This is the entire licensed cannabinoid shelf, worldwide. Three are dronabinol, which is synthetic THC, and one is nabilone, a synthetic analogue of it. That leaves three distinct medicines: a balanced botanical spray, a CBD isolate and, since June 2026, the first high-THC full-spectrum botanical.

1985

Marinol (dronabinol)

CINV; AIDS-related anorexia

Synthetic THC
1985

Cesamet (nabilone)

Chemotherapy-induced nausea

Synthetic THC analogue
2005

Sativex (nabiximols)

MS spasticity

THC:CBD combination
2016

Syndros (dronabinol)

CINV; AIDS-related anorexia

Synthetic THC
2018

Epidiolex / Epidyolex

Refractory epilepsies

CBD isolate
2026

Exilby (VER-01)

Chronic low-back pain

Full-spectrum botanical
n/d

Dronabinol (generic)

CINV; AIDS-related anorexia

Synthetic THC

First approval in any market, from the investigational-products tracker. Generic dronabinol carries no single authorisation date and is shown without one (n/d) rather than guessed.

The companies

Eighty-three companies, and six marketing authorisations between them.

The company tracker holds every business we can identify running, or having run, a clinical trial of a proprietary cannabinoid product in humans, with its lead asset, its lead indication, its furthest stage and the route it chose.

How far each company has got

Phase II47
Phase III13
Phase I12
Approved6
Unknown5

59 of 83 companies have never got a product past Phase II. 13 sit at Phase III and 6 hold an approval.

Furthest stage reached across all of a company’s assets.

Which route they chose

60%30%10%

Single-molecule / synthetic 49Full-spectrum botanical 25Mixed 8

Nearly six in ten chose a single molecule or a synthetic, the route with clean composition-of-matter IP. Only 25 went after the whole-plant botanical, the route that has just produced the field’s newest approval.

Strategic approach across the 82 companies with a route recorded.

Where they are based

United States29
Australia14
Canada13
Israel10
United Kingdom9
Germany4

The US leads with 29 companies, but Australia is second with 14, ahead of Canada, Israel and the UK, and far ahead of Germany at 4 despite Germany hosting the newest approval.

Headquarters country. Six of 13 shown.

The six with a marketing authorisation

GermanyVertanicalExilby (VER-01)
US / UKJazz PharmaceuticalsEpidiolex; JZP378
UKCNX TherapeuticsSativex
USAbbVieMarinol
USBenuviaSyndros
USINSYS TherapeuticsSyndros; CBD oral solution

The pipeline tracker

Open the live pipeline tracker.

One form opens the tracker itself: the products, the companies behind them and the full analysis of the trial base you have been reading extracts from.

01Investigational products trackerAll 114 cannabinoid products in development, filed by stage, composition class and lead indication, including the 12 live Phase III programmes and the approved shelf.
02Pharmaceutical company tracker83 companies developing a cannabinoid medicine in humans, with lead asset, furthest stage and the route each one is betting on.
03The clinical-trial analysisThe full read on all 2,250+ trials: starts, phases, indications, funders, geography and rigour, refreshed as records land.

Already have access? Open the tracker →

Get the pipeline tracker

Free with a work email.

If the form does not load, write to info@cannamonitor.com and we will send you access.

How we build it

Why these numbers hold up.

1
Merged, then taggedRecords are pulled from 13 registry sources and normalised onto one schema: phase, status, condition group, cannabinoid, compound class, dosage form, delivery route, study design, blinding, control type, funder type, sponsor, sites and country. A registry gives you text, and the tag set is what makes it countable.
2
Coverage is measured before anything is publishedEvery derived series is checked for field coverage first, and a series only starts where coverage is real. Two fields failed that test for this page and are named on it.
3
Duplicates are merged, and failures stay on the recordA cross-registry pass in August 2026 collapsed 27 duplicate studies. The 103 terminated trials, 62 withdrawn and 7 discontinued products all remain in the base and in these charts.

How complete the record is, of 2,296 trials

Condition group100%Published
Phase100%Published
Compound class99.9%Published
Sample size93%Published
Start date77%Published
THC:CBD ratio48%Not published
Recruitment statuspartialNot published

Two fields are absent from every chart on this page. The THC:CBD ratio is recorded on only 48% of records, so the compound-class chart uses a field with 99.9% coverage instead. Recruitment status was defaulted by the import for 1,025 records from registries that do not maintain one, so this page counts what is recruiting (427) and what is completed (719), and says which.

Sources: ClinicalTrials.gov, EU CTR (EudraCT), CTIS, ANZCTR, ISRCTN, DRKS, NTR, CTRI, REBEC, IRCT, UMIN, ChiCTR and company disclosures. Cannamonitor Clinical Trials database, 13 registry sources, n = 2,296. Snapshot 24 Aug 2026. This page is a snapshot; the tracker is updated between snapshots.

The data behind this page

This page is a summary, and Decide is the source.

Everything above is one subject, drawn from eight data layers. In Decide those same layers cover 125+ markets and they cross-link, so a trial reaches its product, its sponsor, that company’s deals and earnings, and the market it will launch into. Choose a layer to see inside it.

THE PIPELINEone grapheight layersClinical trials2,250+ trials · 13 registriesInvestigational products114 assets in developmentScience & studies1,956 science items trackedCompanies83 cannabinoid developersEarnings & financials592 reported periodsM&A & funding600+ deals, $40bn+News & Regulatory10,263 items · 275 rulingsCountries & markets127 markets, one schema
Swipe the map sideways →
Every layer cross-links — a trial reaches its product, its sponsor, that company’s deals and earnings, the market it will launch into and the paper behind it. Choose a layer to see inside it.
Layer 01 · 2,296 records, 13 registries
Clinical trials
Every cannabinoid trial we can find, merged onto one schema and tagged record by record — phase, status, indication, cannabinoid, compound class, design, blinding, funder, sponsor and country.
Clinical trials › live Phase III
2,296
trials tracked
13
registries merged
48
countries
2,141
with endpoints recorded
TrialIndicationnStatus
VER-01 radicularRadicular low-back pain810Registered
PROMOTEClinical high-risk psychosis586Registered
ZYN002 open-label ext.Fragile X syndrome550Recruiting
CBD TPM capsulesPrimary insomnia519Recruiting
Swipe the table sideways →
Filter, sort and drill to the registry record. 427 recruiting today, 719 completed.
Layer 02 · 114 assets in development
Investigational products
A trial is an event; a product is a bet. Every cannabinoid asset in human development — what it is made of, how it is delivered, what it is aimed at, how far it has got, and which trials carry it.
Investigational products › Phase III
114
products tracked
87
in clinical trials
12
live at Phase III
7
approved anywhere
ProductCompanyLead indicationClass
Exilby follow-on (VER-01 radicular)VertanicalRadicular low-back painFull‑spectrum
CANPAINCeladonChronic non-cancer painFull‑spectrum
NTI164Neurotech InternationalPaediatric neurodevelopmentFull‑spectrum
YCJ-01Oils4CureTSC epilepsy (adjunct)Full‑spectrum
Swipe the table sideways →
Approved, investigational and discontinued all stay on the record — 7 programmes in here have already failed.
Layer 03 · 1,956 items tagged Science & R&D
Science & studies
Readouts, publications and preclinical work as they land — the Science & R&D slice of the news graph, every item linked to its source and to the company, country and trial it moves.
Science & studies › the last month
1,956
science items tracked
695
in the last 12 months
269
trials with a linked paper
280
with safety findings recorded
Category: Science & R&DCountry: anyCompany: any
AUGForensic study finds 92% of Italian legal cannabis products mislabelled with semi-synthetic cannabinoids20 Aug 2026 · Thermo Fisher · Agilent · Restek
AUGDronabinol reduces PTSD-related nightmares in a randomised controlled trial5 Aug 2026 · Bionorica SE
JULMediPharm Labs reports positive Phase II LiBBY results in dementia agitation14 Jul 2026 · MediPharm Labs
JULAnanda Pharma doses first patient in the ACTiON Phase II trial of MRX1 (CBD) in chemotherapy-induced neuropathy14 Jul 2026 · Ananda Pharma
Every item carries its source link, and 1,937 of the 1,956 carry a country — so a readout reaches the trial, the product and the market it affects.
Layer 04 · 83 developers, cross-linked
Companies
Every business running, or having run, a clinical trial of a proprietary cannabinoid product — profiled and linked to its assets, its trials, its deals, its earnings and the news that moves it.
Companies › developer profile
Vertanical
Pharma developer · Germany
Holder of the first European marketing authorisation for a cannabis-derived medicine, granted 9 June 2026.
Lead asset: Exilby (VER-01)Full-spectrum botanical
Linked recordValue
Marketing authorisationGermany, Jun 2026
Registered trials3 (Phase III)
Lead indicationChronic low-back pain
Company financials🔒
Swipe the table sideways →
83 developers. Only 6 of them hold a marketing authorisation anywhere.
Layer 05 · 592 reported periods
Earnings & financials
Revenue, gross margin, EBITDA, opex, cash and guidance for listed operators and pharma — the answer to whether a company can actually fund the trial it has just registered.
Earnings & financials › cannabinoid pharma
592
reported periods
Quarterly
and annual
Revenue
margin · EBITDA
Linked
to company and deal
CompanyLineLatest
Jazz PharmaceuticalsEpidiolex net revenue, 2025$1.1bn (+9%)
Jazz PharmaceuticalsEpidiolex share of group revenue~25%
CNX TherapeuticsSativex revenue, 2025$16.3m
VertanicalExilby revenue, company projection>$2bn in 2 years
Swipe the table sideways →
Sourced from filings and MD&As. The Vertanical line is a company projection, labelled as one.
Layer 06 · 600+ deals, $40bn+ disclosed
M&A & funding
Who bought whom, who raised what, and what it cost — including the acquisition that built the patent wall every developer on this page has had to engineer around.
M&A & funding › cannabinoid pharma
DatePartiesValueType
May 2021Jazz Pharmaceuticals → GW Pharmaceuticals$7.2bnAcquisition, closed
Nov 2018Constellation Brands → Canopy Growth (38%)C$5.0bnEquity raise, closed
Oct 2025Jazz → CNX Therapeutics (Sativex)UndisclosedDivestment
Aug 2026Curaleaf → Aurora CannabisUS$4.00/shareAnnounced, proposed
Swipe the table sideways →
600+ deals across 21 countries, 2017–today. Withdrawn deals stay on the record.
Layer 07 · 10,263 news items, 275 regulatory records
News & Regulatory
Scheduling, approvals and reimbursement — tracked, translated where the source is not in English, and filterable by country, company and theme. The same graph the science layer reads from, filtered to Regulation.
News & Regulatory › cannabinoid pharma
10,263
news records
3,427
tagged Regulation
4,878
tagged Market
275
regulatory rulings
Category: RegulationCountry: anyCompany: any
DEVertanical wins the first European marketing authorisation for ExilbyRegulatory · 9 Jun 2026
USCannabis moves Schedule I → III, effective 28 Apr 2026Regulatory · §280E relief, legal study sourcing
USBroader DEA hearing runs 29 Jun – 15 Jul 2026Regulatory · scheduling
USExilby granted FDA Breakthrough Therapy DesignationRegulatory · 19 May 2026
10,263 news records across three categories — Market, Regulation and Science & R&D — plus 275 formal regulatory records, each cross-linked to the company, country and asset it moves.
Layer 08 · 127 markets on one schema
Countries & markets
Imports, patients, pricing, reimbursement and regulation, market by market — so a programme can be read against the market it will actually launch into.
Countries & markets › where the trials are
127
markets on file
48
with trial activity
2,168
country tags on trials
One
schema for each
MarketTrialsPhase IIIShare
United States908748%
United Kingdom1134943%
Germany1362317%
Australia661523%
Swipe the table sideways →
The same schema in every market, so two countries can be put side by side without rebuilding the comparison first.

Go deeper

You have the pipeline. Here is what going deeper gives you.

Go deep · Decide

The databases themselves, not the read-out.

The tracker gives you the analysis. Decide gives you the record, which you can query, filter and join across markets and companies.

  • The full clinical-trials databaseAll 2,296 records, every field, down to the registry entry.
  • The full company databaseBeyond the pharma developers: every cannabis company we track, with financials and news.
  • Science and studiesThe published research behind the trials.
  • Country and market dataWhere a programme has a market to launch into.
€1,420 a yearExplore Decide →

Stay current · Essentials

The pipeline moves, and Essentials tells you when.

Essentials keeps you current on every market: the full monthly brief the moment it is written, the news dashboard, and premium insights on the readouts and approvals that move a programme.

€142 a yearSee Essentials →

Questions

The questions people ask about the data.

If yours is not here, ask us.

How many cannabinoid clinical trials are there really?

2,296 on our record as of 24 Aug 2026, merged from 13 registry sources. That is higher than most published counts because most published counts are a ClinicalTrials.gov search, which holds 1,546 of these and misses 750 that exist only in ANZCTR, DRKS, CTRI, ISRCTN, REBEC, IRCT, NTR, UMIN, ChiCTR or the EU registers.

Why doesn’t this page tell me how many trials are active?

Because the field behind that number is not reliable yet. A recent back-population added 1,025 records from registries that do not maintain a live recruitment status, and the import assigned them one. Rather than publish a number built on a default, this page counts what is recruiting (427) and what is completed (719). The status field is being cleaned, and when it is, the figure goes back on the page.

Are duplicate registrations counted twice?

No. A multinational study registered in both ClinicalTrials.gov and a national register can appear as two records, so in August 2026 we ran a cross-registry deduplication over the whole base: 27 duplicate studies, 54 records collapsed to 27. Every merged record is still in the database with its own registry identifier, pointing at the record that survived, so nothing is lost and a future crawl cannot re-create it.

The duplication was almost entirely a European registry problem: 18% of CTIS records and 9% of Dutch NTR records were duplicates, against 0.2% of ClinicalTrials.gov. A further 35 records that look like duplicates are deliberately kept apart: a parent trial and its sub-studies, or a randomised trial and its open-label extension.

Is this a literature review with charts on it?

No. Nothing here is derived from a paper. Every figure is a query against a tagged database of individual trial, product and company records, and the query behind each one is recorded next to it, so refreshing this page is a re-run.

What does the tracker include, and what sits in Decide?

Your work email opens the pipeline tracker, free: the investigational-products database (114 assets), the pharmaceutical-companies database (83 developers) and the full clinical-trial analysis. The full clinical-trials database, the full company database and the science and studies library sit inside Decide.

How often does it update?

Records are added and revised as registries publish. This page is stamped with the snapshot it was built from (24 Aug 2026), and the tracker is always ahead of the page.

Which cannabinoids and products are in scope?

Any trial of a cannabinoid or cannabis-derived intervention in humans: THC, CBD, the minor cannabinoids (90 trials across CBN, CBG, THCV, CBDV, delta-8-THC, CBDA and CBC), whole-plant and broad-spectrum extracts, synthetic analogues such as dronabinol and nabilone, nabiximols, and endocannabinoid-system modulators (79 trials). Observational and mechanistic studies are included and labelled.

Everything on this page is live in Decide, matched to the companies, markets and deals behind each trial.

The tracker shows you the pipeline. Decide gives you the databases underneath it, with 125+ markets beside them.

Already have access? Open the tracker →